文献速递血栓与止血白血病浆细胞疾病

T-DM1联合来那替尼治疗HER2阳性转移性乳腺癌的安全性与疗效:NSABP FB-10研究

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
PubMed 文献 · J Clin Oncol · 2019-08-23

该3+3剂量递增研究评估了T-DM1联合来那替尼在曲妥珠单抗和帕妥珠单抗治疗进展后的HER2阳性转移性乳腺癌患者中的安全性、耐受性和疗效。27例患者接受治疗,确定II期推荐剂量为T-DM1 3.6 mg/kg联合来那替尼160 mg/d。19例可评估患者中12例(63%)达到客观缓解,基线cfDNA ERBB2扩增患者缓解更深更持久。

要点

  • II期推荐剂量为T-DM1 3.6 mg/kg联合来那替尼160 mg/d。
  • 可评估患者客观缓解率为63%(12/19),所有来那替尼剂量水平均见缓解。
  • 基线cfDNA ERBB2扩增患者缓解更深更持久,2例完全缓解者组织高表达总HER2和p95HER2。

核心结论

  • T-DM1联合来那替尼在曲妥珠单抗和帕妥珠单抗治疗进展后的HER2阳性转移性乳腺癌患者中显示出可管理的安全性和令人鼓舞的疗效。
  • 对HER2抗体可能的耐药机制包括HER2受体丢失和p95HER2高表达。

研究设计与样本

  • 3+3剂量递增研究,纳入曲妥珠单抗、帕妥珠单抗和紫杉烷治疗进展的转移性乳腺癌患者。
  • T-DM1 3.6 mg/kg静脉每3周一次,来那替尼口服剂量递增至120、160、200或240 mg/d。
  • 共27例患者接受治疗,跨四个来那替尼剂量水平。

主要发现

  • 第一周期剂量限制性毒性为6例患者3级腹泻和1例3级恶心;无4级腹泻,无5级毒性。
  • 其他3-4级毒性包括恶心(11%)、脱水(11%)、电解质异常(19%)、血小板减少(15%)、转氨酶升高(7%)和乏力(7%)。
  • 19例可评估患者中12例(63%)达到客观缓解,缓解发生于所有来那替尼剂量水平。
  • 基线血浆cfDNA显示27例中10例存在ERBB2(HER2)扩增,这些患者缓解更深更持久。
  • 2例完全缓解者基线组织显示总HER2和p95HER2高表达。

关键数值与推荐

  • II期推荐剂量:T-DM1 3.6 mg/kg联合来那替尼160 mg/d。
  • 客观缓解率:12/19(63%)。
  • 3-4级毒性发生率:恶心11%、脱水11%、电解质异常19%、血小板减少15%、转氨酶升高7%、乏力7%。
  • 基线cfDNA ERBB2扩增:10/27例。

临床怎么用

  • 对于曲妥珠单抗和帕妥珠单抗治疗进展的HER2阳性转移性乳腺癌患者,可考虑T-DM1联合来那替尼160 mg/d。
  • 治疗期间需密切监测腹泻、恶心、电解质异常和血小板减少等毒性。
  • 基线cfDNA ERBB2扩增和p95HER2高表达可能有助于预测缓解深度和持久性。

局限性

  • 样本量小(27例),为剂量递增研究,疗效需进一步验证。
  • 可评估缓解的患者仅19例,客观缓解率基于小样本。
  • 未报告无进展生存期和总生存期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated. We evaluated the safety, tolerability, and efficacy of ado-trastuzumab emtansine (T-DM1) plus neratinib in patients who progressed on trastuzumab plus pertuzumab. PATIENTS AND METHODS: In this 3 + 3 dose-escalation study, patients with metastatic breast cancer who progressed on trastuzumab, pertuzumab, and a taxane were treated with T-DM1 at 3.6 mg/kg intravenously every 3 weeks and dose-escalating neratinib at 120, 160, 200, or 240 mg/d orally. RESULTS: Twenty-seven patients were treated across four dose-levels of neratinib. Dose-limiting toxicity in cycle 1 was grade 3 diarrhea in six patients and grade 3 nausea in one; no patient experienced grade 4 diarrhea, and there were no grade 5 toxicities. Other grade 3 to 4 toxicities included nausea (11%), dehydration (11%), electrolyte abnormality (19%), thrombocytopenia (15%), elevated transaminase levels (7%), and fatigue (7%). Twelve (63%) of 19 evaluable patients had an objective response. Responses occurred at all neratinib doses. Plasma cell-free DNA at baseline showed ERBB2 (HER2) amplification in 10 of 27 patients. Deep and more durable responses occurred in patients with cell-free DNA ERBB2 amplification. Two complete responders had high expression of total HER2 and p95HER2 in baseline tissue. CONCLUSION: We report the recommended phase II dose of T-DM1 3.6 mg/kg and neratinib 160 mg/d for this combination. Possible resistance mechanisms to HER2 antibodies may be loss of the HER2 receptor and high expression of p95HER2. These data provide the basis for an ongoing phase II study to better define the activity of this regimen.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Abraham J, Montero AJ, Jankowitz RC, et al. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. J Clin Oncol. 2019. PMID: 31442103. doi:10.1200/JCO.19.00858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。